- Home
- SUGP vs NXTC Comparison
SUGP vs NXTC Comparison
Compare SUGP & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- NXTC
- Stock Information
- Founded
- SUGP 1998
- NXTC 2015
- Country
- SUGP Hong Kong
- NXTC United States
- Employees
- SUGP N/A
- NXTC N/A
- Industry
- SUGP
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- NXTC Health Care
- Exchange
- SUGP NYSE
- NXTC Nasdaq
- Market Cap
- SUGP 20.3M
- NXTC 23.0M
- IPO Year
- SUGP 2024
- NXTC 2019
- Fundamental
- Price
- SUGP $1.17
- NXTC $0.79
- Analyst Decision
- SUGP
- NXTC Strong Buy
- Analyst Count
- SUGP 0
- NXTC 2
- Target Price
- SUGP N/A
- NXTC $4.00
- AVG Volume (30 Days)
- SUGP 510.4K
- NXTC 201.3K
- Earning Date
- SUGP 01-28-2025
- NXTC 11-07-2024
- Dividend Yield
- SUGP N/A
- NXTC N/A
- EPS Growth
- SUGP N/A
- NXTC N/A
- EPS
- SUGP 0.10
- NXTC N/A
- Revenue
- SUGP $20,252,232.00
- NXTC N/A
- Revenue This Year
- SUGP N/A
- NXTC N/A
- Revenue Next Year
- SUGP N/A
- NXTC N/A
- P/E Ratio
- SUGP $11.40
- NXTC N/A
- Revenue Growth
- SUGP N/A
- NXTC N/A
- 52 Week Low
- SUGP $0.76
- NXTC $0.76
- 52 Week High
- SUGP $5.86
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- SUGP 46.38
- NXTC 36.33
- Support Level
- SUGP $1.09
- NXTC $0.76
- Resistance Level
- SUGP $1.26
- NXTC $0.83
- Average True Range (ATR)
- SUGP 0.14
- NXTC 0.07
- MACD
- SUGP 0.01
- NXTC 0.01
- Stochastic Oscillator
- SUGP 34.15
- NXTC 14.87
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.